Portal de Periódicos da CAPES

Relugolix for the treatment of uterine fibroids

2020; Taylor & Francis; Volume: 21; Issue: 14 Linguagem: Inglês

10.1080/14656566.2020.1787988

1744-7666

M. Rocca, A. Palumbo, Daniela Lico, Alessia Fiorenza, Giovanna Bitonti, S D‘Agostino, C Gallo, Costantino Di Carlo, Fulvio Zullo, Roberta Venturella,

Gynecological conditions and treatments

Uterine fibroids (UF) are benign tumors common in premenopausal women, with strong impact on the health-care systems. For many years, surgery represented the only therapy for symptomatic fibroids. However, clinicians are observing a switch from surgery to noninvasive methods; in particular, medical treatment has been shown to be efficacious in obtaining a bleeding reduction and in ameliorating patient conditions.The authors review the current options available for the treatment of women with UF, with a special focus on the newest one, relugolix. It is an orally active non-peptide Gonadotropin-releasing hormone (GnRH)-receptor antagonist recently licensed for women with symptomatic fibroids. Relugolix is a well-tolerated safe drug; it is effective in inducing a dose-dependent decrease in menstrual blood loss, with faster reduction of heavy menstrual bleeding (HMB) and a greater shrinkage in fibroid volume compared to the current standard of GnRH agonist treatment.Relugolix is a promising drug for the non-surgical treatment of women with UF. To date, the only published data come from a well-selected Japanese female population study while results from worldwide ongoing studies are ongoing in order to confirm the efficacy of this GnRH agonist receptor.